Biological Activity
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease[1][2].
In Vitro
No in vitro data are provided in the current product source. Contact us for further information.
In Vivo
Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Frömter (MWF) rat[1]. Animal Model: Twelve-week-old MWF rat[1] Dosage: 10 mg/kg Administration: P.o.; daily for 4 weeks Result: Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model. Animal Model: Twelve-week-old MWF rat[1] Dosage: 10 mg/kg Administration: P.o.; daily for 4 weeks Result: Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
References & source
[1]. Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403. [2]. González-Blázquez R, et al. Finerenone Attenuates Endothelial
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.